On this page
Key takeaways
● Skin: yes, modestly — but the 2025 stratified meta-analysis found the effect largely disappears in industry-independent, high-quality trials (3). Expect measurable but small change.
● Knee osteoarthritis: yes — Yu 2023 meta-analysis showed standardised mean difference of −0.58 for pain across four RCTs (all rated high risk of bias) (4). Corroborated by a 2024 trial-sequential analysis of 35 RCTs (5).
● Postmenopausal bone: yes at 5 g/day, based on one well-conducted 12-month RCT (6). The evidence base is narrow.
● Muscle building: no — collagen lost head-to-head to whey in a leucine-matched trial (7).
● Hair, nails, and gut: weak evidence, largely industry-funded or extrapolative.
● How to read the evidence: funding source and study quality matter more than the count of positive trials.
Quick answer
Yes for some things, more modestly than the marketing suggests, and honestly worse for others. Hydrolysed collagen shows small-to-moderate improvements in skin, knee osteoarthritis pain, and postmenopausal bone density in randomised trials. But the 2025 American Journal of Medicine meta-analysis found the skin effect largely disappears in industry-independent, high-quality studies — a finding no top-ranking consumer article addresses. Collagen is decisively worse than whey for muscle building. Hair, nail, and gut claims rest on weaker evidence. This is a skeptic-charitable read of what the trials actually show, indication by indication.
Why the honest question is harder than it looks
A search for "does hydrolysed collagen actually work" surfaces two poles. On one side, wellness sites and brand blogs report enthusiastic positive answers backed by meta-analyses. On the other, skeptic content dismisses collagen supplementation as "expensive protein" that will be digested to nothing useful. Both are wrong. The truth is more nuanced and more useful.
The evidence base for hydrolysed collagen is real and larger than for many popular supplements — several dozen randomised trials, multiple meta-analyses, an established mechanism supported by human pharmacokinetic data (9). The effect sizes across skin, joint, and bone outcomes are consistently modest but consistently favourable. The meta-analytic estimates that supplement marketers quote are technically real.
But those pooled estimates are inflated by systematic biases in the underlying trial literature — biases that a small number of methodologically careful analyses have quantified. The most important of these is the 2025 stratified meta-analysis published in the American Journal of Medicine, which we return to shortly. Understanding these biases is what separates an honest evidence review from a marketing summary.
How to read collagen trials — the evidence quality checklist
Before evaluating the indication-by-indication verdicts, a brief framework for reading trials in this category.
Randomisation and blinding
Good trials randomise participants to active or placebo groups, and both participants and outcome assessors are blinded to who received what. Poor trials do neither. For skin outcomes measured by objective devices (corneometry, cutometer, standardised photography), blinding of the assessor is critical because assessor expectations can otherwise influence readings.
Sample size and duration
Adequate sample size to detect a small-to-moderate effect (roughly 40 or more participants per arm) and adequate duration (8–12 weeks minimum for skin outcomes; 6 months for joint outcomes; 12 months for bone) are basic requirements. Small, short trials often report positive effects that fail to replicate in larger, longer designs.
Industry funding
Well-established across the pharmaceutical and nutritional-supplement literature: industry-sponsored trials report positive results more often than independently-funded trials, even after adjusting for methodological quality (14). This is not evidence of fraud — it reflects a mixture of publication bias, selective outcome reporting, choice of comparator, and endpoint definition. In the collagen literature specifically, most trials are funded by ingredient suppliers (Gelita, Rousselot, Nitta) whose products are being tested.
Risk of bias assessment
Cochrane-style risk-of-bias scoring evaluates each trial across domains including randomisation, blinding, incomplete data, and selective reporting. Trials rated "high risk of bias" should be interpreted with caution even when their reported results are positive. In the Yu 2023 knee osteoarthritis meta-analysis, all four included trials were rated high risk of bias (4).
With this framework in hand, let us look at each indication.
Skin — yes, modestly, and with the caveat everyone omits
Skin is the most studied indication for hydrolysed collagen and the one where the marketing runs strongest. Let us go through it carefully.
Two well-conducted meta-analyses establish the pooled effect. The 2021 de Miranda analysis (19 RCTs, n=1,125) reported favourable effects across skin hydration, elasticity, and wrinkles at doses of 2.5–10 g/day over 8–12 weeks (1). The 2023 Pu analysis (26 RCTs, n=1,721) corroborated this with strong statistical signals for both hydration and elasticity (2). Both analyses report that the effect direction and magnitude are similar across bovine, marine, and porcine sources.
These findings, taken at face value, are what supplement marketing quotes. And technically they are real.
The 2025 finding that reframes the picture
In 2025, a stratified meta-analysis published in the American Journal of Medicine took a more careful look at the same evidence base (3). This analysis included 23 RCTs (n=1,474) and split the trials by two variables: funding source (industry-funded vs independent) and methodological quality (high vs low). The pooled overall effect was still statistically significant. But the subgroup analyses told a different story.
In the subgroup of trials not funded by the collagen industry, the effect on skin hydration, elasticity, and wrinkles was no longer statistically significant. In the subgroup of high-quality studies (low risk of bias), the same pattern appeared: effects were not statistically significant. Only industry-funded and lower-quality studies showed significant benefit.
This is not, on its own, proof that hydrolysed collagen does nothing for skin. But it is a strong warning that the headline meta-analytic estimates you see quoted everywhere are likely inflated. The realistic effect size — the effect you should actually expect from supplementation — is smaller than the marketing implies and may be quite close to zero in some skin parameters.
What this means practically
Expect measurable but modest change over 8–12 weeks: a modest improvement in the skin's ability to retain moisture (measured by corneometry), a small increase in cutometer-measured elasticity, and a modest reduction in wrinkle depth on standardised photography. Effect sizes across trials typically fall in the 5–15% range on these outcomes — meaningful but far below the visible transformations shown in advertising imagery.
The 2024 CollaSel Pro RCT (112 healthy women, 10 g/day for 8 weeks, industry-funded) is a representative modern trial with the typical caveat (12) — significant p-values, small effect sizes, industry sponsorship. This is what modern collagen skin trials look like.
Verdict for skin: yes at modest effect sizes, with the honest acknowledgment that the effect may be smaller than marketing suggests and may be close to zero in the highest-quality independent studies. Complement with the larger levers — sun protection, sleep, retinoids — rather than substituting for them. For the fuller treatment see our full skin article.
Knee osteoarthritis pain — yes, with real caveats
The Yu 2023 meta-analysis (4 RCTs, n=507) is the load-bearing evidence (4). Pooled standardised mean difference of −0.58 for knee osteoarthritis pain (95% CI −0.98 to −0.18, p=0.004) — meaningfully above the −0.37 minimum clinically important difference threshold. Adverse events did not differ from placebo. The 2024 García-Coronado trial-sequential meta-analysis (35 RCTs, n=3,165) corroborated the direction of effect across a much larger evidence base (5).
The caveats: all four trials in the Yu 2023 analysis were rated high risk of bias, and most included trials ran three to six months — long enough to demonstrate benefit but not long enough to compare against the multi-year evidence base for weight management and structured exercise, which remain the largest levers for knee osteoarthritis.
Still, for a category dominated by glucosamine and chondroitin (whose evidence is weaker) and by NSAIDs (whose long-term safety is not clean), collagen peptides earn their place as a reasonable adjunct.
Verdict for joint pain: yes, with a moderate effect size in the trial evidence and the caveat that the trials are methodologically imperfect. Continue exercise and weight management as primary interventions. See the full joints article.
Postmenopausal bone — the most interesting result
König 2018 is the anchor trial for bone: 131 postmenopausal women with T-score ≤ −1, randomised to 5 g/day of specific collagen peptides or matched maltodextrin placebo, 12 months of supplementation (6). Result: statistically significant increases in BMD at the lumbar spine and femoral neck versus placebo, with favourable shifts in P1NP (formation marker) and CTX-1 (resorption marker). A four-year open-label follow-up reported progressive gains.
Two things make this result unusually interesting. First, the dose was low — 5 g/day, not the 10–15 g/day used for other indications. Second, BMD is a hard, quantitative outcome measured by DXA scanning — much less susceptible to expectation bias than subjective skin or pain ratings.
The caveats are honest and significant. Most of the bone literature funnels through the Freiburg research group; the trial was funded by Gelita AG (the ingredient supplier). Independent replication by other groups is limited. Bone gains of this magnitude, if durable, would matter clinically — but a single research programme is a fragile foundation.
Verdict for postmenopausal bone: yes at 5 g/day, based on one striking well-conducted trial with a four-year follow-up. Take this as an evidence-aligned adjunct to vitamin D, calcium, weight-bearing exercise, and — where indicated — prescribed pharmacotherapy. Do not substitute collagen for prescribed osteoporosis therapy in diagnosed disease. See the full bones article.
Muscle building — no, honestly
This is where marketing most diverges from science. Collagen is an incomplete protein: it contains no tryptophan at all and roughly one-third the leucine of whey. Leucine is the amino acid that triggers muscle protein synthesis. Collagen is structurally poor for building or preserving muscle.
The most direct test is Oikawa 2020: a 10-week head-to-head comparison of whey versus leucine-matched collagen peptides in young adults doing supervised resistance training (7). Muscle thickness gains were greater in the whey group — even with equalised leucine. The likely reason: whey delivered ~13.9 g of essential amino acids per serving; collagen delivered ~7.7 g, below the threshold for maximal muscle protein synthesis stimulation.
The Zdzieblik 2015 trial in elderly sarcopenic men reported striking lean-mass gains at 15 g/day combined with resistance training (8). But the reported effect sizes were large enough that a published critique in the same journal questioned reproducibility. Independent replications have not clearly emerged.
Verdict for muscle: no. Use a complete protein. Collagen at 10–15 g/day can be a reasonable adjunct for tendon and connective-tissue support around exercise (Shaw 2017 showed 15 g of gelatin plus vitamin C one hour before training raises collagen-synthesis markers (11)) — but it is not a substitute for a complete-protein primary. See the full whey comparison article.
Hair, nails, and gut health — weak evidence
A small number of trials — mostly industry-funded, mostly self-reported outcomes, generally low sample sizes — report improvements in hair thickness, nail strength, and brittle-nail symptoms (10). The biological story (collagen provides amino-acid substrate for keratin) is plausible but indirect. The trial quality is not good enough to support strong claims.
Gut health claims are the weakest link. There is no substantial human trial evidence for hydrolysed collagen specifically improving gut-barrier function. The proposed mechanisms (glycine and glutamine supporting mucosal repair) do not have collagen-specific data behind them; they extrapolate from other supplement categories.
Verdict for hair, nails, gut: weak evidence. Treat any visible hair or nail improvement as a welcome bonus, not the reason to buy. Do not take hydrolysed collagen primarily for gut health — better-supported alternatives exist. See the hair and nails article and the gut health article.
What we still don't know
● How large is the true skin effect in fully independent, high-quality trials? The 2025 stratified analysis suggests small to none (3). More independent RCTs would clarify this.
● Does the König 2018 bone result replicate outside the Freiburg research programme? It has not, yet, in the published literature.
● What are the long-term outcomes beyond 12 months? Almost no evidence base beyond that horizon. Whether continued supplementation for 5 or 10 years compounds benefit, plateaus, or produces no additional effect is genuinely unknown.
● Which molecular-weight fraction drives the strongest signal? Pharmacokinetic evidence suggests lower is somewhat better; clinical outcome evidence is less clear.
● Is the sarcopenia signal from Zdzieblik 2015 reproducible? Not clearly, in independent groups.
Bottom line
Hydrolysed collagen actually works, at modest effect sizes, for some things. Skin: yes, but the true effect is likely smaller than headline meta-analyses suggest, given the 2025 funding-source stratification finding. Knee osteoarthritis pain: yes, with meta-analyses showing meaningful reduction — though bias risk in the underlying trials is a real caveat. Postmenopausal bone: yes at 5 g/day, based on one striking trial. Muscle: no, honestly. Hair, nails, gut: weakly supported. If you take hydrolysed collagen for skin or joint outcomes, expect measurable but modest change over months, and pair it with the larger levers (sun protection, exercise, weight management, vitamin D). If you are taking it for muscle building, use a complete protein instead. If you are taking it for hair or gut outcomes, treat any effect as a bonus. For the indication-anchored dose table and the full pillar picture, see our main guide.
Frequently asked questions
Is there strong evidence hydrolysed collagen works?
For skin, joint, and postmenopausal bone outcomes there is meta-analytic evidence supporting a small-to-moderate effect. The evidence quality is compromised in several important ways: heavy industry funding, high risk of bias in individual trials, small effect sizes, and — importantly — a 2025 stratified analysis showing the skin effect largely disappears in independent, high-quality studies (3). "Strong evidence" would be an overstatement. "Consistent, modest evidence with caveats" is more accurate.
How long before you see results from hydrolysed collagen?
Skin and joint trials typically show measurable changes at 8–12 weeks. Bone benefits, per König 2018, require the full 12 months to develop meaningfully (6). Subjective changes reported earlier by some users should be treated as anecdotal until the timeframe matches the trial data. Discontinuing after two weeks because "nothing is happening" is not aligned with the biology.
Why does the 2025 AmJMed meta-analysis matter so much?
Because it did what other meta-analyses did not: stratified the evidence base by funding source and methodological quality (3). When you look only at trials funded by the collagen industry and lower-quality studies, the skin effect is significant. When you look only at independent and high-quality trials, it disappears. This pattern — well documented across pharmaceutical and supplement literatures (14) — means the pooled estimates that dominate consumer marketing are likely inflated. It does not prove the effect is zero, but it strongly suggests it is smaller than advertised.
Is collagen better than nothing?
For skin, joint, and postmenopausal bone outcomes, probably yes — modestly. The effect over months is small but reproducible across the trial literature. Whether "better than nothing" justifies the cost depends on your budget and priorities relative to other levers (sun protection for skin, exercise and weight management for joints, vitamin D and calcium for bones).
What about the placebo effect?
Well-conducted trials use matched placebos (usually maltodextrin) precisely to control for placebo effects on subjective outcomes. Objective outcomes — DXA-measured bone density, corneometry-measured skin hydration, cutometer-measured elasticity — are much less susceptible to placebo effects than subjective ratings of "how my skin feels" or "how much my knee hurts." The best evidence for hydrolysed collagen (König 2018 bone; the skin device-measured outcomes in Pu 2023) is on objective measures (2,6), making pure placebo an unlikely explanation for the effect direction — though effect magnitude may still be affected by publication and funding-source biases.
Should I take it?
If you are aged 40+ concerned about skin ageing, or have knee osteoarthritis, or are a postmenopausal woman worried about bone density — reasonable candidate, at modest expected benefit, at the trial-anchored dose for your goal. If you take it for muscle building, hair, nails, or gut — probably no; there are better options. The main pillar guide has the full "who this is for" section.
References
1. de Miranda RB, Weimer P, Rossi RC. Effects of hydrolyzed collagen supplementation on skin aging: a systematic review and meta-analysis. Int J Dermatol 2021. https://pubmed.ncbi.nlm.nih.gov/34553487/
2. Pu SY, Huang YL, Pu CM, et al.. Effects of oral collagen for skin anti-aging: a systematic review and meta-analysis. Nutrients 2023. https://doi.org/10.3390/nu15092080
3. Lee SH, Kim Y, Han SH, et al.. Effects of collagen supplements on skin aging: a systematic review and meta-analysis of RCTs. Am J Med 2025. https://doi.org/10.1016/j.amjmed.2025.03.018
4. Yu Y, Cheng K, Zhao W, et al.. Analgesic efficacy of collagen peptide in knee osteoarthritis: a meta-analysis of RCTs. J Orthop Surg Res 2023. https://pubmed.ncbi.nlm.nih.gov/37715244/
5. García-Coronado JM, et al.. Effect of collagen supplementation on osteoarthritis symptoms: a meta-analysis. Osteoarthr Cartil 2024. https://doi.org/10.1016/j.joca.2024.01.005
6. König D, Oesser S, Scharla S, Zdzieblik D, Gollhofer A. Specific collagen peptides improve bone mineral density and bone markers in postmenopausal women. Nutrients 2018. https://pubmed.ncbi.nlm.nih.gov/29337906/
7. Oikawa SY, Holloway TM, Phillips SM, et al.. Whey protein supplementation is superior to leucine-matched collagen peptides to increase muscle thickness during a 10-week resistance training program in untrained young adults. Int J Sport Nutr Exerc Metab 2020. https://doi.org/10.1123/ijsnem.2019-0319
8. Zdzieblik D, Oesser S, Baumstark MW, Gollhofer A, König D. Collagen peptide supplementation in combination with resistance training improves body composition and increases muscle strength in elderly sarcopenic men. Br J Nutr 2015. https://pubmed.ncbi.nlm.nih.gov/26353786/
9. Iwai K, Hasegawa T, Taguchi Y, et al.. Identification of food-derived collagen peptides in human blood after oral ingestion of gelatin hydrolysates. J Agric Food Chem 2005. https://pubmed.ncbi.nlm.nih.gov/16076145/
10. Hexsel D, Zague V, Schunck M, et al.. Oral supplementation with specific bioactive collagen peptides improves nail growth. J Cosmet Dermatol 2017. https://pubmed.ncbi.nlm.nih.gov/28786550/
11. Shaw G, Lee-Barthel A, Ross ML, Wang B, Baar K. Vitamin C-enriched gelatin supplementation before intermittent activity augments collagen synthesis. Am J Clin Nutr 2017. https://pubmed.ncbi.nlm.nih.gov/27852613/
12. Various authors. CollaSel Pro RCT — safety and efficacy of hydrolyzed collagen peptide supplementation in adult females. J Clin Med 2024. https://pmc.ncbi.nlm.nih.gov/articles/PMC11432272/
13. Ioannidis JPA. Why most published research findings are false. PLoS Med 2005. https://pubmed.ncbi.nlm.nih.gov/16060722/
14. Lundh A, Lexchin J, Mintzes B, Schroll JB, Bero L. Industry sponsorship and research outcome (Cochrane methodology review). Cochrane Database Syst Rev 2017. https://pubmed.ncbi.nlm.nih.gov/28207928/